New Two-Pronged cancer drug enters human trials

NCT ID NCT04977453

Summary

This study is testing a new, experimental drug called GI-101 in people with advanced cancers that have spread. The main goals are to find a safe dose and see if the drug, given alone or with other approved cancer medicines, can help shrink tumors. The trial will enroll about 317 adults with specific advanced solid tumors, including certain lung, kidney, bladder, and cervical cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact

  • Carolina Biooncology Institute

    RECRUITING

    Huntersville, North Carolina, 28078, United States

    Contact

  • Chungnam National University Hospital

    RECRUITING

    Daejeon, Daejeon, 65015, South Korea

    Contact

  • Korea University Anam Hospital

    RECRUITING

    Seoul, Seongbuk-gu, 02841, South Korea

    Contact

  • The Catholic University of Korea St. Vincent's Hospital

    RECRUITING

    Suwon, Kyeonggi-do, 16247, South Korea

    Contact

  • Tisch Cancer Institute (TCI), Icahn School of Medicine

    RECRUITING

    New York, New York, 10029-5674, United States

    Contact

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.